Published in Front Oncol on May 28, 2012
Intratumor heterogeneity: evolution through space and time. Cancer Res (2012) 3.45
Inter and intratumour heterogeneity: a barrier to individualized medical therapy in renal cell carcinoma? Front Oncol (2012) 0.97
Anti-angiogenic and anti-metastatic activity of synthetic phosphoethanolamine. PLoS One (2013) 0.88
Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens. Oncotarget (2015) 0.79
Clear cell renal cell carcinoma: a comparative study of histological and chromosomal characteristics between primary tumors and their corresponding metastases. Virchows Arch (2017) 0.75
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med (2012) 44.56
Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A (1996) 29.54
Tumour evolution inferred by single-cell sequencing. Nature (2011) 19.13
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med (2003) 14.59
Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature (2010) 14.50
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol (2010) 13.03
The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol (2010) 5.04
Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol (2007) 4.40
Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res (2008) 4.02
Sunitinib efficacy against advanced renal cell carcinoma. J Urol (2007) 3.14
Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res (2005) 2.29
PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer. Clin Cancer Res (2010) 2.13
Intratumor genomic heterogeneity in breast cancer with clonal divergence between primary carcinomas and lymph node metastases. Breast Cancer Res Treat (2006) 2.04
von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol (2008) 1.87
Clonality assessment and clonal ordering of individual neoplastic crypts shows polyclonality of colorectal adenomas. Gastroenterology (2010) 1.83
ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease. Eur Urol (2011) 1.80
Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas. Am J Surg Pathol (2011) 1.76
Sunitinib malate for the treatment of solid tumours: a review of current clinical data. Expert Opin Investig Drugs (2006) 1.51
HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysis. Breast Cancer Res Treat (2011) 1.29
Evaluation of the clonal relationship between primary and metastatic renal cell carcinoma by comparative genomic hybridization. Am J Pathol (1999) 1.25
HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care. Clin Cancer Res (2011) 1.19
Genetically heterogeneous and clonally unrelated metastases may arise in patients with cutaneous melanoma. Am J Surg Pathol (2007) 1.13
Intratumoral heterogeneity of von Hippel-Lindau gene deletions in renal cell carcinoma detected by fluorescence in situ hybridization. Cancer Res (1998) 1.09
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med (2007) 39.39
Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med (2007) 30.94
The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (2002) 18.30
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 13.52
Sunitinib in patients with metastatic renal cell carcinoma. JAMA (2006) 11.33
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 9.05
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol (2009) 8.16
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol (2009) 6.86
Regulation of Raf-1 by direct feedback phosphorylation. Mol Cell (2005) 5.88
Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res (2004) 5.88
Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol (2008) 5.27
Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res (2009) 5.10
Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst (2007) 5.10
alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA (2002) 5.07
Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol (2007) 4.40
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol (2004) 4.25
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 4.24
Human Proteinpedia enables sharing of human protein data. Nat Biotechnol (2008) 4.21
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol (2013) 3.79
The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. Am J Surg Pathol (2013) 3.68
Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 3.65
Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol (2005) 3.49
The protein composition of mitotic chromosomes determined using multiclassifier combinatorial proteomics. Cell (2010) 3.26
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol (2013) 3.19
Sunitinib efficacy against advanced renal cell carcinoma. J Urol (2007) 3.14
Renal mass biopsy--a renaissance? J Urol (2007) 3.12
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol (2008) 3.00
Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med (2007) 2.90
Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res (2008) 2.84
Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Lancet Oncol (2012) 2.84
An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. Cancer Cell (2011) 2.78
The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol (2010) 2.73
A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res (2007) 2.71
Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol (2009) 2.69
Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res (2010) 2.61
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol (2012) 2.61
Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol (2006) 2.50
Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. AJR Am J Roentgenol (2010) 2.44
Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res (2009) 2.32
Surgical resection of renal cell carcinoma after targeted therapy. J Urol (2009) 2.29
Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Clin Cancer Res (2010) 2.26
Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer (2007) 2.25
Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist (2008) 2.22
Histone H2A.Z cooperates with RNAi and heterochromatin factors to suppress antisense RNAs. Nature (2009) 2.19
Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors. Proc Natl Acad Sci U S A (2005) 2.14
Clinically aggressive solid pseudopapillary tumors of the pancreas: a report of two cases with components of undifferentiated carcinoma and a comparative clinicopathologic analysis of 34 conventional cases. Am J Surg Pathol (2005) 2.12
Structural and thermodynamic properties of selective ion binding in a K+ channel. PLoS Biol (2007) 2.10
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer (2010) 2.10
Renal angiomyolipoma: clinicopathologic study of 194 cases with emphasis on the epithelioid histology and tuberous sclerosis association. Am J Surg Pathol (2009) 2.10
TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients. Prostate (2010) 2.05
Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J Urol (2008) 2.03
Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. J Clin Oncol (2004) 2.02
Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol (2008) 2.00
Protein phosphatase 2A positively regulates Ras signaling by dephosphorylating KSR1 and Raf-1 on critical 14-3-3 binding sites. Curr Biol (2003) 1.98
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci U S A (2011) 1.97
Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med (2002) 1.95
MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. J Clin Invest (2013) 1.89
von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol (2008) 1.87
Renal epithelioid angiomyolipoma with atypia: a series of 40 cases with emphasis on clinicopathologic prognostic indicators of malignancy. Am J Surg Pathol (2010) 1.87
Fusion of ALK to the Ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor. Genes Chromosomes Cancer (2003) 1.86
Adult cystic nephroma and mixed epithelial and stromal tumor of the kidney are the same disease entity: molecular and histologic evidence. Am J Surg Pathol (2009) 1.84
The ubiquitin ligase gp78 promotes sarcoma metastasis by targeting KAI1 for degradation. Nat Med (2007) 1.81
A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res (2009) 1.79
Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer (2008) 1.70
F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. J Clin Oncol (2003) 1.70
CK2 Is a component of the KSR1 scaffold complex that contributes to Raf kinase activation. Curr Biol (2006) 1.69
Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy. Urology (2010) 1.68
Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol (2007) 1.66
The effect of sunitinib on primary renal cell carcinoma and facilitation of subsequent surgery. J Urol (2012) 1.65
A susceptibility locus at chromosome 3p21 linked to familial nasopharyngeal carcinoma. Cancer Res (2004) 1.65
Multicenter study evaluating the Vitek MS system for identification of medically important yeasts. J Clin Microbiol (2013) 1.64
Recent progress in the management of advanced renal cell carcinoma. CA Cancer J Clin (2007) 1.62
Immune synapse formation requires ZAP-70 recruitment by ezrin and CD43 removal by moesin. J Cell Biol (2007) 1.61
Diverse roles of HP1 proteins in heterochromatin assembly and functions in fission yeast. Proc Natl Acad Sci U S A (2009) 1.60
microRNA-141 is involved in a nasopharyngeal carcinoma-related genes network. Carcinogenesis (2010) 1.59
Evaluation of the Verigene Gram-positive blood culture nucleic acid test for rapid detection of bacteria and resistance determinants. J Clin Microbiol (2013) 1.59